Speaker

Professor Huang Xiaojun, who graduated from Sun Yat-sen University with an MD and Peking University with a PhD, is a renowned hematologist specialized in hematopoietic stem cell transplantation, cellular therapy and malignant haematological diseases. He has been serving as the Head of Peking University Institute of Hematology and the Director of National Clinical Research Center for Hematologic Diseases, P.R. China and the Director of the hematology department of Peking University People’s Hospital since 2005. He is also the academician of Chinese Academy of Engineering, the fellow of Chinese Academy of Medical Sciences, and the foreign corresponding academician of French National Academy of Medicine.

Since 1996, Professor Huang has pioneered the exploration of haploidentical hematopoietic stem cell transplantation (haplo-HSCT). With persistent efforts, he established a series of key techniques of non T-cell depleted haploidentical transplantation, which gradually developed into the novel G-CSF/ATG-based “Beijing Protocol”, increasing the 3-year survival rate from approximately 20% to about 70% in haploidentical transplantation treating leukemia. This system has made significant strides in overcoming the global challenge of donor scarcity, achieving in a new era where “everyone has a donor”. Nowadays, the “Beijing Protocol” techniques have been adopted in over 190 centers in China. The protocol has also been extended to countries worldwide and holds a dominant position globally in the field of haploidentical stem cell transplantation.